How LONSURF May Help
Clinical Trial Results
LONSURF has been proven to help some patients:
- Live longer
- Reduce the progression of cancer
- Maintain the same level of functioning longer
SUNLIGHT Trial: LONSURF with Bevacizumab for Colon or Rectal Cancer
The SUNLIGHT clinical trial was a study of 492 patients that looked at the effectiveness and safety of LONSURF used together with bevacizumab compared to LONSURF alone for patients who had already received at least 2 types of treatment for their advanced colorectal cancer. The primary objective was overall survival. Some key secondary objectives were progression-free survival (PFS) and the time to deterioration of Eastern Cooperative Oncology Group Performance Status (ECOG PS).
Overall survival
Median overall survival
Overall survival is the time from when the patient starts treatment until they pass away. Patients taking LONSURF with bevacizumab had a median overall survival of 10.8 months compared to 7.5 months in the patients receiving only LONSURF—a 3.3‑month improvement. That means half of the patients in the group that received LONSURF with bevacizumab lived less than 10.8 months but the other half lived longer than that.
Progression-free survival
Median progression-free survival (PFS)
Progression-free survival is a measure of how long someone is on treatment before their cancer starts to grow. Patients taking LONSURF with bevacizumab had a median progression-free survival of 5.6 months compared to 2.4 months in the patients receiving only LONSURF—a 3.2‑month improvement.
Measuring daily function
ECOG Performance Status score is a way to measure how well a patient is functioning in daily life, including things like taking care of themselves, walking around, or working. On the scale, 0 means someone is fully active and has no restrictions while 5 means they have passed away. So, the lower your ECOG Performance Status score, the better.
| Score | ECOG Performance Status |
|---|---|
| 0 | Fully active |
| 1 | Ambulatory and able to carry out light work but restricted in strenuous activity |
| 2 | Bedbound less than 50% of waking hours and capable of self‑care |
| 3 | Bedbound more than 50% of waking hours and capable of limited self‑care |
| 4 | Bedbound, completely disabled and incapable of self‑care |
| 5 | Deceased |
Median time to ECOG PS score increasing to 2 or more
In the LONSURF + bevacizumab group, the median time to ECOG Performance Status score going from 0 or 1 to 2 or more was 9.3 months. The LONSURF-only group had a median time of 6.3 months. So patients who received LONSURF + bevacizumab stayed at a lower, better, ECOG Performance Status longer than patients who received only LONSURF.
RECOURSE Trial: Colorectal Cancer Treatment with LONSURF Alone
The RECOURSE clinical trial was a study of 800 patients that looked at the effectiveness and safety of LONSURF compared to placebo for patients who had already received at least 2 types of treatment for their advanced colorectal cancer. The primary objective was overall survival. Some key secondary objectives were progression-free survival (PFS) and the time to deterioration of Eastern Cooperative Oncology Group Performance Status (ECOG PS).
Overall survival
Median overall survival
Overall survival is the time from when the patient starts treatment until they pass away. Patients taking LONSURF had a median overall survival of 7.2 months compared to 5.2 months in the patients receiving placebo—a 2‑month improvement. That means half of the patients in the group that received LONSURF lived less than 7.2 months but the other half lived longer than that.
Progression-free survival
Progression-free survival is a measure of how long someone is on treatment before their cancer starts to grow. Patients taking LONSURF had a median progression-free survival of 2.0 months compared to 1.7 months in the patients receiving placebo.
Measuring daily function
ECOG Performance Status score is a way to measure how well a patient is functioning in daily life, including things like taking care of themselves, walking around, or working. On the scale, 0 means someone is fully active and has no restrictions while 5 means they have passed away. So, the lower your ECOG Performance Status score, the better.
| Score | ECOG Performance Status |
|---|---|
| 0 | Fully active |
| 1 | Ambulatory and able to carry out light work but restricted in strenuous activity |
| 2 | Bedbound less than 50% of waking hours and capable of self‑care |
| 3 | Bedbound more than 50% of waking hours and capable of limited self‑care |
| 4 | Bedbound, completely disabled and incapable of self‑care |
| 5 | Deceased |
Median time to ECOG PS score increasing to 2 or more
In the LONSURF group, the median time to ECOG Performance Status score going from 0 or 1 to 2 or more was 5.7 months. The placebo group had a median time of 4.0 months. So patients who received LONSURF stayed at a lower, better, ECOG Performance Status longer than patients who received the placebo.
TAGS Trial: Stomach Cancer Treatment with LONSURF
The TAGS clinical trial was a study of 507 patients that looked at the effectiveness and safety of LONSURF compared to placebo for patients who had already received at least 2 types of treatment for their advanced stomach cancer. The primary objective was overall survival. Some key secondary objectives were progression-free survival (PFS) and time to deterioration of Eastern Cooperative Oncology Group Performance Status (ECOG PS).
Overall survival
Median overall survival
Overall survival is the time from when the patient starts treatment until they pass away. Patients taking LONSURF had a median overall survival of 5.7 months compared to 3.6 months in the patients receiving only placebo. That means half of the patients in the group that received LONSURF lived less than 5.7 months but the other half lived longer than that.
Progression-free survival
Progression-free survival is a measure of how long someone is on treatment before their cancer starts to grow. Patients taking LONSURF had a median progression-free survival of 2.0 months compared to 1.8 months in the patients receiving only placebo.
Measuring daily function
ECOG Performance Status score is a way to measure how well a patient is functioning in daily life, including things like taking care of themselves, walking around, or working. On the scale, 0 means someone is fully active and has no restrictions while 5 means they have passed away. So, the lower your ECOG Performance Status score, the better.
| Score | ECOG Performance Status |
|---|---|
| 0 | Fully active |
| 1 | Ambulatory and able to carry out light work but restricted in strenuous activity |
| 2 | Bedbound less than 50% of waking hours and capable of self‑care |
| 3 | Bedbound more than 50% of waking hours and capable of limited self‑care |
| 4 | Bedbound, completely disabled and incapable of self‑care |
| 5 | Deceased |
Median time to ECOG PS score increasing to 2 or more
In the LONSURF group, the median time to ECOG Performance Status score going from 0 or 1 to 2 or more was 4.3 months. The placebo group had a median time of 2.3 months. So patients who received LONSURF alone stayed at a lower, better, ECOG Performance Status longer than patients who received placebo.
How it Works
LONSURF consists of two medicines in the same tablet
- Trifluridine may help prevent tumor growth by interfering with the tumor's DNA
- Tipiracil helps trifluridine work longer
If you have colon or rectal cancer, LONSURF may be used together with bevacizumab (also referred to by the brand name Avastin®), which may help slow or stop blood supply to the tumor. You may have previously received bevacizumab as part of an earlier line of therapy.